Loading clinical trials...
Loading clinical trials...
This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated lo...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Allist Pharmaceuticals, Inc.
NCT06028633 · Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, and more
NCT05648071 · Advanced Non-squamous Non-Small-Cell Lung Cancer
Anhui Province cancer hospital
Hefei, Anhui
Pecking Union Medical College Hospital
Beijing, Beijing Municipality
Cancer Hospital Chinese Academy Of Medical Sciences
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions